Mingjian Piao
机构：Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital · ORCID：0009-0005-4981-5942
发表论文 22 篇 · 总被引 262 次 · h-index 6
代表论文
- Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study (2024 · EClinicalMedicine · 被引 154)
- Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis (2023 · Cancer Immunology Immunotherapy · 被引 25)
- Conversion surgery intervention versus continued systemic therapy in patients with a response after PD-1/PD-L1 inhibitor-based combination therapy for initially unresectable biliary tract cancer: a retrospective cohort study (2024 · International Journal of Surgery · 被引 21)
- Single-cell transcriptomic analysis deciphers the inflammatory microenvironment characterized by CXCL9+ fibroblasts and ACKR1+ endothelial cells in immune-related myocarditis (2025 · Journal of Translational Medicine · 被引 14)
- Conversion Surgery after Immune Checkpoint Inhibitor-Based Combination Therapy for Initially Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study (2025 · Liver Cancer · 被引 9)
- Peripheral blood PD-1+ T lymphocytes as biomarkers in liquid biopsies for solid tumors: Clinical significance and prognostic applications (2025 · International Immunopharmacology · 被引 9)